Cemiplimab’s latest price reference and detailed explanation of cost differences for different specifications in the global market

Cemiplimab (Cemiplimab) is a PD-1 inhibitor that has attracted much attention in the field of global tumor immunotherapy. However, it is not yet on the market in China and has not been included in medical insurance. Therefore, there is no official domestic price yet. For domestic patients, they can only rely on overseas drug purchasing channels to obtain the drug, such as cross-border medical institutions, international pharmacies or regulated overseas direct mail platforms. Prices fluctuate greatly, mainly depending on factors such as the country of supply, shipping costs, channel markups, and exchange rate changes. Because they are imported immunotherapy drugs, their basic costs are relatively high, and coupled with transportation and medical cold chain requirements, the final price is usually higher than that of general targeted drugs.

In overseas markets, cimepri monoclonal generic drugs are currently mainly American and EU versions. The two are basically the same in terms of ingredients, specifications and clinical uses. The differences are mainly reflected in the supply system and market pricing strategy. Common specifications are 350mg/7mL (50mg/mL), which are sold in single tubes or boxes in most countries. The price of the American version is usually higher. Without reimbursement from medical insurance, the price of each box is about 40,000 to 100,000 yuan. This high cost is related to its status as an innovative immune drug, high production costs, and the overall price level in the field of cancer immunotherapy. In addition, the complex cost structure of the medical system in the United States has also pushed up the retail price of the drug.

The price of the European version converted into RMB is similar to that of the American version, but there are obvious differences between different countries. For example, drug prices in Western European countries are generally high, while public bidding prices in some Eastern European countries are slightly lower. However, due to restrictions on cross-border circulation, most patients still mainly obtain American or Western European versions of drugs through regular international pharmacies. It should be noted that price changes are usually significantly affected by exchange rate fluctuations, especially the fluctuation of the US dollar and the euro against the RMB, which will directly affect the final cost of drug purchase borne by patients.

Currently, there are no generic drugs of cimepilimab on the market worldwide, which means that the market lacks alternative versions with more competitive prices. Therefore, if patients use this drug for a long time, their financial burden will be relatively heavy. When patients consider purchasing drugs overseas, they should give priority to formal channels with legal qualifications, traceable drug sources, and original manufacturer certification to avoid mistakenly purchasing products of unknown origin due to low prices. At the same time, since the drug is administered intravenously and needs to be used under the supervision of professionals in medical institutions, a doctor's evaluation must be completed before purchasing the drug to ensure that the treatment process is standardized and safe.

Keyword tag:

Cimepilimab,PD-1inhibitors, immunotherapy, price, global market, specification cost, accessibility, overseas drug purchase, original drug, generic drug

Reference materials:https://pubmed.ncbi.nlm.nih.gov/?term=cemiplimab